Literature DB >> 26002110

Neoadjuvant chemotherapy for ovarian cancer: do we have enough evidence?

Sokbom Kang1.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 26002110     DOI： 10.1016/S0140-6736(14)62259-5

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  8 in total

1.  Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline.

Authors:  Alexi A Wright; Kari Bohlke; Deborah K Armstrong; Michael A Bookman; William A Cliby; Robert L Coleman; Don S Dizon; Joseph J Kash; Larissa A Meyer; Kathleen N Moore; Alexander B Olawaiye; Jessica Oldham; Ritu Salani; Dee Sparacio; William P Tew; Ignace Vergote; Mitchell I Edelson
Journal:  Gynecol Oncol       Date:  2016-08-08       Impact factor: 5.482

2.  Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline.

Authors:  Alexi A Wright; Kari Bohlke; Deborah K Armstrong; Michael A Bookman; William A Cliby; Robert L Coleman; Don S Dizon; Joseph J Kash; Larissa A Meyer; Kathleen N Moore; Alexander B Olawaiye; Jessica Oldham; Ritu Salani; Dee Sparacio; William P Tew; Ignace Vergote; Mitchell I Edelson
Journal:  J Clin Oncol       Date:  2016-08-08       Impact factor: 44.544

3.  Neoadjuvant chemotherapy for Patients with advanced epithelial ovarian cancer: A Meta-Analysis.

Authors:  Long-Jia Zeng; Chun-Lin Xiang; Yi-Zhen Gong; Yan Kuang; Fang-Fang Lu; Su-Yi Yi; Yue Zhang; Meng Liao
Journal:  Sci Rep       Date:  2016-11-02       Impact factor: 4.379

4.  Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer.

Authors:  Xia Xu; Fei Deng; Mengmeng Lv; Binhui Ren; Wenwen Guo; Xiaoxiang Chen
Journal:  J Ovarian Res       Date:  2016-12-02       Impact factor: 4.234

Review 5.  Emerging Trends in Neoadjuvant Chemotherapy for Ovarian Cancer.

Authors:  Ami Patel; Puja Iyer; Shinya Matsuzaki; Koji Matsuo; Anil K Sood; Nicole D Fleming
Journal:  Cancers (Basel)       Date:  2021-02-05       Impact factor: 6.639

6.  Are There Survival Differences Between Women with Equivalent Residual Disease After Interval Cytoreductive Surgery Compared with Primary Cytoreductive Surgery for Advanced Ovarian and Peritoneal Cancer?

Authors:  David Pierce Mysona; Sharad Ghamande; Jin-Xiong She; Lynn Tran; Paul Tran; Bunja J Rungruang; John K Chan; Victoria Bae-Jump; Paola A Gehrig
Journal:  Ann Surg Oncol       Date:  2020-11-05       Impact factor: 5.344

7.  Upregulation of centrosomal protein 55 is associated with unfavorable prognosis and tumor invasion in epithelial ovarian carcinoma.

Authors:  Weijing Zhang; Chunhao Niu; Weiling He; Teng Hou; Xiaoying Sun; Liqun Xu; Yanna Zhang
Journal:  Tumour Biol       Date:  2015-11-28

8.  Characteristics and survival of ovarian cancer patients treated with neoadjuvant chemotherapy but not undergoing interval debulking surgery.

Authors:  Ying L Liu; Olga T Filippova; Qin Zhou; Alexia Iasonos; Dennis S Chi; Oliver Zivanovic; Yukio Sonoda; Ginger J Gardner; Vance A Broach; Roisin E O'Cearbhaill; Jason A Konner; Carol Aghajanian; Kara Long Roche; William P Tew
Journal:  J Gynecol Oncol       Date:  2020-01       Impact factor: 4.401
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.